Week in Review: May 9–13

Edit The Scientist 13 May 2016
A drug that singles out Staphylococcus aureus leaves gut-dwelling microbiota largely intact, a mouse study shows....

European Stock Benchmarks Slip as Oil Slides

Edit The Street 13 May 2016
European stocks slipped on Friday, following oil and Asian benchmarks lower. In London the FTSE 100 was recently down 0.18% at 6,093.33 ... East coast time ... West Africa-focused gold miner Aureus Mining, which is listed in London and Toronto, plunged almost 17% in London after reporting first-quarter results without news on when production would resume at its Liberia mine after a problem with a detoxification circuit ... ....

European Stock Markets Fall After Eurozone GDP Data

Edit The Street 13 May 2016
European stocks slipped on Friday, following oil and Asian benchmarks lower, as data showed the Eurozone economy had expanded slightly less than expected in the first quarter ... West Africa-focused gold miner Aureus Mining, which is listed in London and Toronto, plunged more than 19% after reporting first-quarter results without news on when production would resume at its Liberia mine after a problem with a detoxification circuit ... ....

NEW LIBERTY TEMPORARILY SUSPENDS GOLD PLANT OPERATIONS (Aureus Mining Inc)

Edit Public Technologies 12 May 2016
Aureus Mining Inc) ... Aureus Mining Inc. ('Aureus' or the 'Company'), the TSX and AIM listed West African gold producer, reports that operations at the New Liberty Gold Mine ('New Liberty') have been temporarily suspended as a consequence of problems with the detoxification circuit in the process plant ... Aureus and Bea Mountain Mining Corp ... Contact Information Aureus Mining Inc ... About Aureus Mining Inc ... Aureus Mining Inc....

AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update (AmpliPhi Biosciences Corporation)

Edit Public Technologies 12 May 2016
'We acquired additional bacteriophage assets, presented in vitro data for AB-PA01 for Pseudomonas aeruginosa, dosed our first patient and successfully completed the first cohort in our Phase I clinical trial of AB-SA01 for the treatment of Staphylococcus aureus infections in patients with chronic rhinosinusitis....

Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial and First Quarter 2016 Financial Results (Dipexium Pharmaceuticals Inc)

Edit Public Technologies 12 May 2016
(Source. Dipexium Pharmaceuticals Inc) ... (Nasdaq ... Conference Call & Webcast Information ... Based on a compilation of available clinical and microbiology data, Locilex is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA) ... $ -....

Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV(R) (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference (Theravance Inc)

Edit Public Technologies 11 May 2016
Findings highlight specific HABP/VABP patient populations, including those with methicillin-resistant Staphylococcus aureus (MRSA), for which VIBATIV may serve as an appropriate treatment ... aureus Infection ... aureus infections studied to date ... Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA ... aureus when alternative treatments are not suitable....

Otago studies supported by Health Research Council (University of Otago)

Edit Public Technologies 11 May 2016
(Source. University of Otago). Wednesday, 11 May 2016 12.45pm ... These grants cover a range of topics including the feasibility of ... $145,459 ... $149,982 ... Shiga-toxin producing Escherichia coli (STEC) and Staphylococcus aureus ... aureus causes serious skin and bloodstream infections ... aureus in cattle and humans, and about how humans interact with cattle and the environment ... aureus to humans, maintaining treatment options for infections ... $149,908....

BRIEF-Aureus says New Liberty temporarily suspending gold plant operations

Edit Reuters 10 May 2016
* Operations temporarily suspended as a consequence of problems with detoxification circuit in process plant ....

ContraFect Announces First Quarter 2016 Results (ContraFect Corporation)

Edit Public Technologies 10 May 2016
In the last quarter, ContraFect made significant progress in advancing its first-in-class lysin product candidate CF-301 intended for the treatment of Staphylococcus aureus (Staph aureus) bloodstream infections including endocarditis ... CF-301 is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staph aureus, a major cause of blood stream infections, or bacteremia....

AmpliPhi to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on May 13, 2016 (AmpliPhi Biosciences Corporation)

Edit Public Technologies 10 May 2016
(Source. AmpliPhi Biosciences Corporation). May 10th 2016. AmpliPhi to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on May 13, 2016 Category. Latest News ... The passcode is 10677209 ... ### ... AmpliPhi is currently conducting a Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients and expects to report final data in the second half of 2016 ... (noodl....

Allergan Reports Strong First Quarter 2016 Continuing Operations Performance with 48% Increase in Net Revenue to $3.8 Billion and 15% Growth in Non-GAAP Diluted EPS to $3.04 (Allergan plc)

Edit Public Technologies 10 May 2016
The expanded label includes a single-dose administered as a 30-minute intravenous (IV) infusion of DALVANCE for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible Gram-positive bacteria in adults, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA)....
×